ArticleInternational journal of molecular sciences2017
Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination.
Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- A systematic review on metabolomics-based diagnostic biomarker discovery and validation in pancreatic cancer.Metabolomics : Official journal of the Metabolomic Society · 2018Pooled it
- Article
- Inhibition of JAK2/STAT3 signaling pathway by panaxadiol limits the progression of pancreatic cancer.Aging · 2021Article
- Differential Tissue Metabolic Signatures in IgG4-Related Ophthalmic Disease and Orbital Mucosa-Associated Lymphoid Tissue Lymphoma.Investigative ophthalmology & visual science · 2021Article
- Article
- Article
- Overexpression of hydroxyproline via EGLN/HIF1A is associated with distant metastasis in pancreatic cancer.American journal of cancer research · 2020Article
- Developing a preoperative serum metabolome-based recurrence-predicting nomogram for patients with resected pancreatic ductal adenocarcinoma.Scientific reports · 2019Article
- Review and Comparison of Cancer Biomarker Trends in Urine as a Basis for New Diagnostic Pathways.Cancers · 2019Review
- Metabonomic Variation of Exopolysaccharide fromOncoTargets and therapy · 2019Article
- Identification of ENTPD8 and cytidine in pancreatic cancer by metabolomic and transcriptomic conjoint analysis.Cancer science · 2018Article
- Elevated Polyamines in Saliva of Pancreatic Cancer.Cancers · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the clinical use of serum metabolomics to discriminate malignant cancers including pancreatic cancer (PC) from malignant diseases, such as biliary tract cancer (BTC), intraductal papillary mucinous carcinoma (IPMC), and various benign pancreaticobiliary diseases. Capillary electrophoresismass spectrometry was used to analyze charged metabolites. We repeatedly analyzed serum samples (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.